USG-guided Steroid Injection Treatment: Efficacy of in Patients With Bifid Median Nerve Diagnosed Carpal Tunnel Syndrome Versus With Non-bifid Median Nerve Diagnosed Carpal Tunnel Syndrome:A Single-blind Randomized Controlled Study

Various median nerve anatomical variations have been reported in the literature.One of these is the bifid median nerve.Due to its relatively higher cross-sectional area, it can facilitate compression of the median nerve in the carpal tunnel.Therefore, bifid median nerve is relatively common in patients with CTS.Some studies have shown that the bifid median nerve has an effect on surgical failure in the treatment of carpal tunnel syndrome.Apart from surgical treatment, perineural injection with corticosteroids is a treatment method that has been used for a long time in the treatment of mild and moderate carpal tunnel syndrome.It is controversial whether bifid median nerve has a negative effect on treatment effectiveness.When looking at the literature, there is no previous study on this subject.With the introduction of ultrasound into our daily practice, the frequency of ultrasound-guided perineural injections has increased.Ultrasound allowed us to see variations in the median nerve before injection.The aim of the study is to compare the effectiveness of steroid injection in patients with CTS with bifid median nerve and patients with CTS with non-variant median nerve.It is also to investigate whether this anatomical variation has a negative effect on the treatment.

开始日期2024-09-15

申办/合作机构-

NCT05981118

/ Enrolling by invitation临床2/3期IIT

Comparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant)

The purpose of this prospective study is to evaluate the degree of post-inflammatory pigmentation alteration on legs of study subjects treated with two different psoriasis treatments. Betamethasone dipropionate 0.05% cream is a high potency steroid that is commonly used to alleviate the inflammation of psoriasis. Tapinarof is another medication approved for psoriasis; tapinarof activates aryl hydrocarbon receptors to downregulate inflammatory cytokines (such as interleukin [IL]-17) which play a large role in psoriasis. Study subjects will be randomized to receive one of these medications and will be followed to monitor for PIPA. Photographs will be taken to help evaluate visual changes. The Taylor Hyperpigmentation scale will be used to grade the area and severity of hyperpigmentation and hypopigmentation; severity of erythema, burning, peeling, and dryness will also be recorded. This will allow us to understand the effects of two standard-of-care psoriasis medications to better treat patients.

开始日期2024-07-15

申办/合作机构

Wake Forest School of Medicine

[+1]

ACTRN12623001181695

/ Completed临床4期

A pilot dose duration-response study using a branded (marketed) formulation betamethasone dipropionate called Diprosone® OV ointment to determine the appropriate dose duration (ED50) for use in a pivotal in vivo bioequivalence study and using participants who demonstrate adequate vasoconstriction to topical steroids.

开始日期2024-05-01

申办/合作机构

Zenith Technology Corp. Ltd.

100 项与倍他米松二丙酸酯相关的临床结果

登录后查看更多信息

100 项与倍他米松二丙酸酯相关的转化医学

登录后查看更多信息

100 项与倍他米松二丙酸酯相关的专利（医药）

登录后查看更多信息

1,103

项与倍他米松二丙酸酯相关的文献（医药）

2025-03-01·JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES

Chromatographic retention assisted in-silico prediction of anticancer potential of glucocorticoids on cancer cell lines

Article

作者: Elkady, Ehab F ; Farouk, Faten ; Sharaky, Marwa ; Sayed, Rawda M

Glucocorticoids (GCs) are hallmarks of anti-inflammatory activity. They are used as adjuvant therapy in oncology medications to alleviate some of the associated side effects. Although recent research has indicated that GCs have favorable anticancer potential, some scientific evidence suggests a pro-proliferation impact of GCs on cancer cells. This may create a scientific confusion on the utility of GCs and the choice of which GC enhances the anticancer potential and mitigates the negative effect. Accurate in-silico prediction and correct ranking of biological activity may be limited by the impact of the physicochemical interaction between small molecules and biological membranes. Chromatographic retention is inherently dependent on the physicochemical properties of the test molecule. It can scale the relative hydrophobicity and tentatively indicate the membrane permeability. In this study, the relationship between the in-silico binding affinity, the chromatographic retention and the in-vitro anticancer activity was investigated. Fifteen GCs were chromatographically separated on an Inertsil® C18 (4.6 * 250 mm; 5 μm) HPLC column. The binding affinity of the test GCs was determined on three receptors involved in cancer cell proliferation (topoisomerase II (TOPII), glucocorticoid receptor (GR) and ATP-binding cassette (ABCG2)). The antiproliferative potential of the test steroids was determined as per their IC₅₀. The correlation between chromatographic retention and the binding affinity to the observed IC₅₀ was investigated by multiple linear regression (MLR). Results revealed that some GCs exhibited a remarkably favorable inhibitory potential against cancer cell lines over normal cell lines. Our data indicated a significant correlation between the retention times of different GCs and the determined binding affinity, especially to the GR (r² = 0.677; p = 0.011) and the estrone sulphate (ESS) binding site of the ABCG2 (r² = 0.643; p = 0.018). Concurrently, the retention times were well correlated to the observed IC₅₀ on the colorectal cancer cell lines (r² = 0.580; p = 0.038) and the hypopharyngeal cell lines (r² = 0.638; p = 0.019). Significant MLR models (n = 4) correlating the retention times of the tested steroids and the binding affinity to the observed IC₅₀ were created. The MLR model correlating the retention times and the ABCG2_ESS binding affinity to the IC₅₀ on lung cancer was the most significant (p = 0.004). The accuracy of the model was 107.12 ± 29.18 % indicating good IC₅₀ prediction abilities. In conclusion, chromatographic retention can be employed as a low-cost and simple auxiliary tool for improving the in-silico prediction of the in-vitro activities of small molecules.

2024-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey

Article

作者: López Estebaranz, José Luis ; Kurzen, Hjalmar ; Galván, Jordi

BACKGROUND:

Psoriasis significantly impacts patients' quality of life (QoL). Dissatisfaction and non-adherence are major barriers associated with topical treatments. A cream based on the polyaphron dispersion (PAD) Technology containing a fixed-dose of calcipotriol (CAL) and betamethasone dipropionate (BDP) was designed for a patient-friendly psoriasis management. The CAL/BDP PAD-cream demonstrated efficacy, convenience, and safety/tolerability in clinical trials.

OBJECTIVES:

This research assesses the real-world use, perception, satisfaction, and adherence of CAL/BDP PAD-cream among plaque psoriasis patients.

METHODS:

Between September-November 2023, psoriasis patients from Spain and Germany using or having used CAL/BDP PAD-cream for >2 weeks were recruited via Wefight network to complete a 30-questions online survey. Anonymized results were pooled for descriptive statistical analysis.

RESULTS:

The survey was completed by 129 patients (mean age: 43 years; 66% females; mean psoriasis duration: 12 years). Most patients (93%) were satisfied with CAL/BDP PAD-cream. The 66% reported high adherence (visual analogue scale 80-100) and 91% preferred CAL/BDP PAD-cream to their previous topical(s). Patients highlighted its ease/convenience of application, tolerability, and lack of itching/burning.

CONCLUSIONS:

Psoriasis patients treated with CAL/BDP PAD-cream in a real-world setting show high satisfaction, good adherence, and a positive perception of the product, suggesting that favorable outcomes observed in clinical trials translate to real clinical practice.

2024-12-31·The Journal of dermatological treatment

Evaluation of psoriasis patients with long-term topical corticosteroids for their risk of developing adrenal insufficiency, Cushing’s syndrome and osteoporosis

Article

作者: Ozturk Unsal, Ilknur ; Gonul, Muzeyyen ; Erdem, Betul ; Ozdemir Sahingoz, Seyda

PURPOSE:

In this study, we will investigate the possible side effects of psoriasis patients using long-term topical corticosteroids (TCS) such as adrenal insufficiency, Cushing's Syndrome (CS) and osteoporosis and determine how these side effects develop.

MATERIAL AND METHODS:

Forty-nine patients were included in the study. The patients were divided into two groups based on the potency of the topical steroid they took and the patients' ACTH, cortisol and bone densitometer values were evaluated.

RESULTS:

There was no significant difference between the two groups regarding the development of surrenal insufficiency, CS and osteoporosis. One patient in group 1 and 4 patients in group 2 were evaluated as iatrogenic CS. ACTH stimulation tests of these patients in group 2 showed consistent results with adrenal insufficiency, while no adrenal insufficiency was detected in the patient in Group 1. Patients who used more than 50g of superpotent topical steroids per week compared to patients who used 50g of superpotent topical steroids per week. It was identified that patients who used more than 50g of superpotent topical steroids had significantly lower cortisol levels, with a negatively significant correlation between cortisol level and the amount of topical steroid use (p < .01).Osteoporosis was detected in 3 patients in group 1 and 8 patients in Group 2. Because of the low number of patients between two groups, statistical analysis could not be performed to determine the risk factors.

CONCLUSIONS:

Our study is the first study that we know of that investigated these three side effects. We have shown that the development of CS, adrenal insufficiency and osteoporosis in patients who use topical steroids for a long time depends on the weekly TCS dosage and the risk increases when it exceeds the threshold of 50 grams per week. therefore, our recommendation would be to avoid long-term use of superpotent steroids and to choose from the medium-potent group if it is to be used.

项与倍他米松二丙酸酯相关的新闻（医药）

2024-03-14

·PRNewswire

Psoriasis in America - Insights into Psoriasis Patient Demographics, Quality of Life, Information-seeking Behaviors, HCP Engagement and Treatment Experiences

DUBLIN, March 14, 2024 /PRNewswire/ -- The "Psoriasis in America 2023: Understanding the Psoriasis Patient Experience" report has been added to ResearchAndMarkets.com's offering. Approximately 7.5 million people in the United States have psoriasis. This Psoriasis in America report provides a comprehensive look at life for those living with psoriasis. Using detailed quantitative data, it gives a full picture of the psoriasis patient experience - from symptoms to treatment to HCP relationships to quality of life - so you can make informed, strategic decisions, identify opportunities, and understand potential challenges. The report offers an in-depth look at the psoriasis patient experience. This large-scale, patient-reported data leverages vital quantitative insights essential to understanding key touchpoints in the psoriasis patient journey, including condition management, HCP engagement, quality of life, treatment experience and satisfaction, and much more. This report lifts the curtain on life with psoriasis, giving stakeholders an actionable look at the behaviors, attitudes, perceptions, needs, and experiences of people living with the condition. Data can be used to inform strategic decisions, including product communications, competitive assessments, concept development, landscape analyses, patient journey overlays, and forecasting inputs. This report also addresses important questions that stakeholders may not even know to ask while offering valuable insights into must-have patient-reported data points not available anywhere else. Add-on custom data analysis opportunities are also available for an additional cost - please see the report following purchase for more information. The analyst reaches millions of people through its portfolio of 45+ condition-specific online health communities - including PlaquePsoriasis.com - to provide information, connection, and support to patients and caregivers in the U.S. This report includes a deep-dive into: Psoriasis patient demographics Age, gender, ethnicity, marital status, children, employment status, income, location, insurance, and other health conditions Impact of psoriasis on quality of life Severity, impact on quality of life, symptoms experienced, and what patients wish others better understood Information-seeking behaviors Information sources used, plus topics of interest HCP engagement Primary HCP seen for condition, satisfaction with HCP, and discussion about brands aware of/not used Psoriasis treatment awareness and experiences Aided awareness of specific treatments, treatment experience, satisfaction with current treatments, perceived control with current treatment plan, and interest/participation in clinical trials Key questions answered in this report: To what extent do people say psoriasis impacts their overall quality of life? What's the average number of flares in the past year? What do patients wish others understood about psoriasis? What percentage of patients see a specialist for psoriasis treatment? What treatments have the highest aided brand awareness among patients? What percentage of patients use a biologic? How many patients feel their psoriasis is well-controlled on their current treatment plan? What percentage of patients are likely to switch or add new treatments in the next six months? What medications have patients discussed with their HCP? What are the top online resources people with psoriasis use to find information? What kinds of content and information do patients search for? What percentage of patients search for information on treatment options? Methodology Psoriasis in America consists of: A 20-minute online quantitative survey, covering demographics, comorbidities, quality of life/impact, HCP interactions, as well as treatment awareness, experiences, and discussions Qualitative patient insights from open-ended responses Additional details: Fielded: January 16, 2023 to April 14, 2023 Convenience sample of 490 respondents diagnosed with psoriasis Respondents are age 18+, living in the U.S., and are recruited from proprietary online health communities and recruiting partners Key Topics Covered: Respondent Demographics Research Highlights Condition Status and Quality of Life Severity and Exacerbations Symptoms Experienced Impact on Quality of Life Qualitative Patient Insights Information-Seeking Behaviors Resources Used to Manage Health Types of Content/Information Sought Treatment Awareness and Experiences Primary HCP Seen for Psoriasis Care Aided Brand Awareness of Treatments Treatment Usage Condition Control on Current Treatment and Clinical Trial Interest Treatment Discussions with HCP Appendix with All Data Charts and Distributions Brands and treatments mentioned in this report include: Topical corticosteroid (such as hydrocortisone) BRYHALIT (halobetasol propionate) lotion DesOwen (desonide) SERNIVOT (betamethasone dipropionate) SORILUXT Foam (calcipotriene) TACLONEX (calcipotriene and betamethasone) TAZORAC (tazarotene) VECTICAL (calcitriol) VTAMA (tapinarof) ZITHRANOLT-RR (anthralin) ZORYVET (roflumilast) Acitretin (SORIATANE) ARAVA (leflunomide) Azathioprine (such as IMURAN, AZASAN) Cyclosporine (such as Sandimmune, NEORAL, RESTASIS) Methotrexate (eg, Rheumatrex), also sometimes given as an injection OTEZLA (apremilast) PLAQUENIL (hydroxychloroquine) RINVOQ (upadacitinib) SOTYKTUT (deucravacitinib) Sulfasalazine (Azulfidine) XELJANZ/XELJANZ XR (tofacitinib citrate) AMJEVITAT (adalimumab-atto) Hide until launched in US AVSOLA (infliximab-axxq) CIMZIA (certolizumab) COSENTYX (secukinumab) CYLTEZO (adalimumab-adbm) Hide until launched in US ENBREL (etanercept) ERELZIT (etanercept-szzs) Hide until launched in US HULIO (adalimumab-fkjp) Hide until launched in US HUMIRA (adalimumab) HYRIMOZ (adalimumab-adaz) Hide until launched in US ILUMYAT (tildrakizumab-asmn) INFLECTRA (infliximab-dyyb) IXIFIT (infliximab-qbtx) Hide until launched in US ORENCIA (abatacept) REMICADE (infliximab) RENFLEXIST (infliximab-abda) SIMPONI (golimumab) SIMPONI ARIA (golimumab for infusion) SILIQT (brodalumab) SKYRIZI (risankizumab-rzaa) STELARA (ustekinumab) TALTZ (ixekizumab) TREMFYA (guselkumab) For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets

2023-05-11

·drugs

The Most Common Allergy Medicines

THURSDAY, May 11, 2023 -- If you suffer from allergies, you know how bothersome and uncomfortable the sneezing and itchy eyes can be. These symptoms are more than irritating — they impact day-to-day activities like work, school, sports, sleeping and even eating. Not only that, but allergies can also cause more serious health problems such as asthma and even anaphylaxis, a life-threatening allergic reaction. Allergies are a common health condition affecting almost one-third of adults in the United States and just over one-quarter of children under 17, according to the U.S. Centers for Disease Control and Prevention . But there is relief at hand: Here’s what you need to know about the most common allergy medicines, the type of allergies they treat, how they work and common side effects. Antihistamines This type of allergy medicine is very effective in relieving allergy symptoms. Mayo Clinic explains this drug type works by blocking histamine, “a symptom-causing chemical released by your immune system during an allergic reaction.” Antihistamines are available as an over-the-counter medication or as a prescription allergy medicine, and they are sold in oral form, as a nasal spray or as eyedrops. This allergy medicine treats symptoms of indoor and seasonal allergies. Common side effects of antihistamines include drowsiness, dry mouth, dizziness, blurred or double vision, mucous thickening and low blood pressure. Common antihistamines include: Oral Loratadine (Alavert, Claritin) Cetirizine (Zyrtec) Diphenhydramine (Benadryl) Doxylamine (Vicks NyQuil, Tylenol Cold and Cough Nighttime) Fexofenadine (Allegra) Nasal spray Olopatadine (Patanase) Eyedrops Ketotifen (Zaditor) Leukotriene modifiers Leukotriene modifiers prevent or lessen the symptoms of allergic rhinitis (hay fever) and allergic asthma. The Cleveland Clinic explains that leukotrienes are chemicals released in the body when you come in contact with an allergen. This causes symptoms like a runny nose and coughing. Leukotriene inhibitors block the effects leukotrienes have on the body or “stop your body from producing them.” This allergy medicine treats symptoms of indoor and seasonal allergies. Leukotriene inhibitors can cause side effects such as cold or flu symptoms, headache, diarrhea, fatigue and itchy skin or rash. More serious side effects like depression, thoughts of suicide, hives, trouble breathing, vomiting and yellowing of the skin or eyes can occur. You should seek medical treatment in these cases. Common leukotriene inhibitors include: Montelukast (Singulair) Zafirlukast (Accolate) Zileuton (Zyflo) Corticosteroids Corticosteroids treat mild to severe allergy symptoms by reducing inflammation caused by your body’s reaction to an allergen. Corticosteroids are available in several forms including pills and liquids, nasal sprays, inhalers, creams and eyedrops. They treat allergic inflammation caused by indoor and seasonal allergens as well as insect stings. Severe allergic reactions are treated with oral corticosteroids, according to the Mayo Clinic. Side effects vary depending on the medication form, but can include increased blood glucose levels, high blood pressure, nosebleeds, mouth and throat irritation, and skin irritation. Common corticosteroids by form include: Pills and liquids Prednisolone (Prelone) Methylprednisolone (Medrol) Nasal sprays Budesonide (Rhinocort) Mometasone (Nasonex) Inhalers Fluticasone (Flovent) Mometasone (Asmanex Twisthaler) Creams Betamethasone (Dermabet, Diprolene) Desonide (Desonate, DesOwen) Eyedrops Fluorometholone (Flarex, FML) Loteprednol (Alrex, Lotemax) Immunotherapy Immunotherapy works by modifying the immune system and its reaction to allergens. It’s not used for immediate allergy symptom relief but is a long-term allergy treatment. Immunotherapy treatments (or allergy shots) are prescription medicines. "Allergy shots can be helpful for patients with seasonal and year-round allergies," Miranda Curtiss , an assistant professor at the University of Alabama at Birmingham School of Medicine, said in a recent article . "However, these are a long-term investment that require planning to continue therapy for three to five years for maximal benefit. Asthmatics who want to start allergy shots need to have their asthma under good control first before starting shots." With allergy shots, you are exposed to an allergen over and over until your immune system becomes desensitized and no longer reacts to the allergen, the Mayo Clinic says. This type of treatment is commonly given as allergy shots (subcutaneous immunotherapy, or SCIT), but is also available in a form given under the tongue (sublingual immunotherapy, or SLIT). With SCIT, injections are given in your doctor’s office where they can monitor for adverse reactions. Treatment starts with the “build-up phase,” which is once or twice a week, and decreases to a maintenance dose which is once every two to four weeks. Sublingual immunotherapy treatment, like subcutaneous immunotherapy, also exposes you to allergens over a period of time, with the goal of building immunity to the allergen. SLIT tablets are available by prescription and taken daily. Immunotherapy is used to treat seasonal and indoor allergies, as well as insect stings. Side effects include watery eyes, sneezing, mild asthma symptoms, a rash at the injection site, tiredness and headaches. In rare cases, life-threatening reactions such as throat swelling and difficulty breathing can occur. Regardless of the type of allergy or your symptoms, there are options for relief. Reach out to your health care provider to learn more about which remedies are best for you. Posted May 2023

免疫疗法

2023-02-11

·生物制品圈

“不死的癌症”——银屑病研发进展最新汇总

前言银屑病作为一种免疫介导的慢性皮肤病，对患者的生活质量有重大影响。银屑病的治疗主要依据发病程度，轻度至中度疾病主要依赖局部治疗，中度至重度疾病通常需要全身给药。近年来生物制剂如TNF-α抗体、IL-17A抗体、IL-12/23抗体，以及小分子化药PDE4抑制剂，JAK抑制剂等均在中重度的银屑病患者中表现出较好的治疗效果。本文概述了银屑病治疗的主要药物类型，并对目前处于研发前沿的药物进行了汇总。图1 银屑病的发病机制01银屑病银屑病是一种以青壮年为主要发病人群的自身免疫性疾病，全球发病率在2-3%。有多种发病类型，包括斑块型银屑病（寻常型银屑病），滴状银屑病，脓疱状银屑病和红皮病型银屑病等。银屑病病人常伴随多种并发症，如银屑性关节炎、淋巴癌、心血管疾病、高血压，糖尿病以及忧郁症等。银屑病常易复发，且目前尚不能完全治愈，长期的疾病折磨会让多数患者存在较大的心理压力和经济负担。银屑病的病理特征是角质形成细胞增生和T细胞、树突状细胞、巨噬细胞和中性粒细胞的浸润，目前被认可的发病机制是以IL-23/Th17为轴的慢性炎症反应。髓系树突状细胞释放IL-23和IL-12，激活产生IL-17的T细胞、Th1细胞和Th22细胞，产生丰富的银屑病细胞因子IL-17、IFN-γ、TNF和IL-22。这些细胞因子介导角质形成细胞的过度增殖和趋化因子的释放，参与银屑病炎症反应[1]。02治疗现状银屑病是一种慢性复发性疾病，通常需要长期治疗。治疗方法的选择取决于疾病的严重程度。根据银屑病患者病变的临床严重程度（PASI评分）、受影响体表面积的百分比（BSA评分）和患者的生活质量，常分为轻度或中度，重度银屑病。● 轻度至中度银屑病一般可以进行局部涂抹治疗。a.糖皮质激素根据激素效果不同，一般用于轻中度银屑病患者的糖皮质激素为弱效和中效糖皮质激素。常用的弱效激素有地奈德和氢化可的松等。中效激素包括糠酸莫米松、丁酸氢化可的松和丙酸氟替卡松等。长期使用激素膏剂会产生多种不良反应，如皮肤萎缩、烧灼和瘙痒感、毛细血管扩张、诱发或加重局部感染、银屑病皮损加重及皮损反跳等不良反应。b.口服视黄醇阿维A酸和其他类视黄醇是用于减少皮肤细胞产生治疗银屑病的药物，副作用包括皮肤干燥和肌肉酸痛。c.维生素D类似物卡泊三醇、骨化三醇和他卡西醇等合成形式的维生素D抑制细胞的增殖，促进角质细胞分化，可减缓皮肤细胞的生长。可单独使用，也可与外用糖皮质激素联用。皮肤刺激是导致停药的常见副作用。d.钙调磷酸酶抑制剂他克莫司（Protopic）和吡美莫司（Elidel）等钙调磷酸酶抑制剂通过抑制IL-2和干扰素-γ的合成来阻断T细胞的激活，可缓解皮疹并减少鳞屑形成。长期使用可能增加患皮肤癌和淋巴瘤的风险。e.芳香烃受体(AHR)抑制剂银屑病患者中角质形成细胞表达的一种配体依赖性转录因子：AHR表达增加，AHR抑制剂的外用药本维莫德乳膏可以使皮肤细胞分化正常化，改善皮肤屏障。毛囊炎和接触性皮炎是最常见的副作用。f.磷酸二酯酶4(PDE-4)抑制剂银屑病的发病与PDE-4的过度表达有关，抑制PDE4能够增加cAMP水平，导致参与银屑病病理生理的免疫调节因子下调。外用药罗氟司特于2022年7月被美国FDA批准治疗斑块状银屑病（尚未进入中国市场），目前报道最多的副作用是高血压、头痛、腹泻和鼻咽炎。图2 银屑病的评估治疗方案[2]● 中度至重度银屑病通常需要全身治疗a.光疗法治疗银屑病的光疗最常用的是窄谱中波紫外线和PUVA（紫外线UVA 与光敏剂联合疗法），作用机制包括细胞凋亡和免疫抑制。最适合光疗的银屑病主要有点滴型银屑病和斑块型银屑病。常用的窄谱中波紫外线对于皮肤深层和内脏没有任何影响，但常产生一定的副作用，如皮肤发炎、瘙痒，干燥，甚至是恶心和头痛。b.超强糖皮质激素和强效糖皮质激素超强效糖皮质激素有丙酸卤倍他索、丙酸氯倍他索和卤米松。强效糖皮质激素包括氯氟舒松和倍他米松二丙酸酯。长期使用或过度使用强效皮质类固醇可能会使皮肤变薄，而且随着时间的推移，外用糖皮质激素可能会变得无效。c.免疫抑制剂甲氨蝶呤和环孢素等免疫抑制剂减少皮肤细胞的产生和抑制免疫系统来缓解银屑病，但副作用较大，长期服用需要接受健康检查。d. Nrf2刺激剂Almirall SA的Nrf2刺激剂富马酸二甲酯于2017年被欧盟批准治疗斑块状银屑病，目前尚未进入中国市场。e. PDE4抑制剂安进（Amgen）的PDE4抑制剂阿普斯特是2021年12月被获批用于治疗斑块状银屑病的口服小分子药物，治疗效果显著，大多数不良事件的严重程度为轻度至中度。f.JAK抑制剂百时美施贵宝（BMS）的TYK2抑制剂Deucravacitinib（氘可来昔替尼）于2022年9月在日本被批准用于治疗红皮病性银屑病、寻常性银屑病和脓胞型银屑病。g.生物制剂TNF-α抑制剂、IL-12/23抑制剂、IL-17抑制剂和IL-23抑制剂等注射用药在银屑病的治疗中表现出较好的效果，但可能增加严重感染风险，因此仅供短期使用，可与其他治疗方法交替使用。表1 治疗银屑病的生物制剂上市现状03药物研发前沿目前针对银屑病的药物研发，仍是抗体类的生物制剂为主，不过也不乏PDE4抑制剂的身影(详见表2)。利用IL-12和IL-23共有的p40亚基研发的IL-12/IL-23抗体药物在银屑病方面的研究正如火如荼的开展，目前AVT-04已在美国提交申请上市，而且全球有10种药物处于临床3期研发阶段。IL-23抗体也有2款药物进入针对银屑病治疗的临床3期阶段。TNF-α单克隆抗体在银屑病治疗领域的研发工作仍不减热度，北京神州细胞的SCT-630已经在国内申请上市，另外有3款国内机构研发的药物和一款美国机构研发的药物处于临床3期阶段。在银屑病治疗领域，IL-17A抗体药物的研发热度也高涨不下，目前有5款IL-17A抗体药物处于临床3期阶段。其中有4款是国内机构所研发，分别为三生国健、恒瑞医药、智翔医药和百奥泰生物科技有限公司。PDE4抑制剂在银屑病领域逐渐崭露头角，近两年分别有外用药和口服药被审批上市。目前大部分PDE4抑制剂处于临床2期研发阶段，另外Pefcalcitol已在美国申请上市，或许成为用于治疗银屑病的下一个PDE4外用药。表2 临床3期和申请上市阶段的银屑病领域药物除了上述已经进入临床3期阶段的靶点药物外，临床2期阶段的药物有PDE4抑制剂如HPP-737、LEO-29102、ME-3183、Orismilast、PF-07038124、QY101、DC-591042和KPG-612等，JAK抑制剂如泽璟生物的盐酸杰克替尼、辉瑞的Brepocitinib、诺诚健华的ICP-332和LEO Pharma A/S的Delgocitinib等，Nrf2刺激剂如ALZ-001和Tepilamide fumarate。此外还有研究发现IL-2通过诱导T细胞激酶，以及MicroRNAs均在银屑病病程中发挥作用，也有望是未来银屑病治疗的新方向。04总结银屑病是一种免疫相关的慢性皮肤疾病，由于发病周期长，容易复发，而且无法痊愈，严重影响患者的生活质量。目前针对银屑病的治疗主要是依据患者的发病程度，轻中度患者一般使用外用药物，中重度患者通常需要全身治疗。目前银屑病的药物研发方向主要是IL-12/23 p40抗体，IL-17A抗体，TNF-α抗体等生物制剂，以及PDE4抑制剂，JAK抑制剂，Nrf2刺激剂等小分子化药。随着对银屑病发病机制的深入，也不断涌现有望发展为治疗银屑病的新靶点和新方向。参考资料：1.Lowes, Michelle A et al. “Immunology of psoriasis.” Annual review of immunology vol. 32 (2014): 227-55. doi:10.1146/annurev-immunol-032713-1202252.Nast, Alexander et al. “S3 Guideline for the treatment of psoriasis vulgaris, update - Short version part 1 - Systemic treatment.” Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG vol. 16,5 (2018): 645-669. doi:10.1111/ddg.135163.Lé, Ana Maria, and Tiago Torres. “New Topical Therapies for Psoriasis.” American journal of clinical dermatology vol. 23,1 (2022): 13-24. doi:10.1007/s40257-021-00649-w3．Mayoclinic官网4. 智慧芽官网5. 新视界官网6. 其他公开信息在抗体圈微信公众号回复“JPM23”可下载60 家药企PPT合集。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

临床结果免疫疗法临床终止临床研究

100 项与倍他米松二丙酸酯相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01637	倍他米松二丙酸酯	D07XC01 A07EA04 R01AD06	DBSALT000851

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
斑块状银屑病	美国	Primus Pharmaceuticals, Inc.	2016-02-05
皮炎	日本	Iwaki Seiyaku Co., Ltd.	2008-06-01
淋巴瘤	日本	Iwaki Seiyaku Co., Ltd.	2008-06-01
银屑病	日本	Iwaki Seiyaku Co., Ltd.	2008-06-01
大疱性皮肤淀粉样变性	日本	Shionogi & Co., Ltd.	1983-08-18
药物性皮炎	日本	Shionogi & Co., Ltd.	1983-08-18
红斑	日本	Shionogi & Co., Ltd.	1983-08-18
肉芽肿	日本	Shionogi & Co., Ltd.	1983-08-18
昆虫咬伤和螫伤	日本	Shionogi & Co., Ltd.	1983-08-18
瘢痕疙瘩	日本	Shionogi & Co., Ltd.	1983-08-18
扁平苔藓	日本	Shionogi & Co., Ltd.	1983-08-18
盘状红斑狼疮	日本	Shionogi & Co., Ltd.	1983-08-18
良性家族性天疱疮	日本	Shionogi & Co., Ltd.	1983-08-18
色素性紫癜性疹	日本	Shionogi & Co., Ltd.	1983-08-18
糠疹	日本	Shionogi & Co., Ltd.	1983-08-18
痒疹	日本	Shionogi & Co., Ltd.	1983-08-18
炎症	美国	Organon & Co.	1983-07-27
湿疹	日本	Shionogi & Co., Ltd.	1979-08-27
瘙痒	日本	Shionogi & Co., Ltd.	1979-08-27
嗜皮菌病	美国	Schering Corp.	1976-04-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
2型糖尿病	临床2期	美国	Primus Pharmaceuticals, Inc.	2014-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02527421 (CTgov)	临床3期	斑块状银屑病	3	DFD01 Spray (DFD01 Spray Group 1)	範鹹憲願蓋膚淵襯艱網 = 夢鏇糧襯獵餘製餘鹹網繭範簾壓繭艱鑰鹽膚鑰 (淵襯獵鹹築襯衊壓鏇繭, 襯觸壓觸醖憲夢蓋築憲 ~ 窪餘醖廠膚窪簾廠鏇窪) 更多	-	2021-10-21
				DFD01 Spray (DFD01 Spray Group 2)	範鹹憲願蓋膚淵襯艱網 = 範鹹艱範築簾構鹹鹽願繭範簾壓繭艱鑰鹽膚鑰 (淵襯獵鹹築襯衊壓鏇繭, 蓋鏇願選餘鏇憲顧築繭 ~ 獵積積淵餘鹽遞範廠獵) 更多
NCT01967069 (CTgov)	临床3期	银屑病	277	DFD01 Spray (DFD01 Spray)	願廠觸選蓋簾範夢淵鑰 = 鑰遞構艱鏇鬱鹹顧鑰壓簾構鹹鏇鹹積膚夢餘淵 (顧繭範糧壓廠顧繭繭壓, 衊醖襯膚鏇壓選蓋艱願 ~ 襯夢鏇顧壓膚獵顧簾築) 更多	-	2017-03-13
				Vehicle Spray (Vehicle Spray)	願廠觸選蓋簾範夢淵鑰 = 蓋構壓廠窪衊糧蓋鬱範簾構鹹鏇鹹積膚夢餘淵 (顧繭範糧壓廠顧繭繭壓, 餘憲鏇鏇淵網遞選築構 ~ 製齋襯醖鏇淵觸襯糧壓) 更多
NCT02070965 (BDS1307, CTgov)	临床2期	2型糖尿病 \| 斑块状银屑病	75	DFD01 Spray (DFD01 Spray Group 1)	鹹膚獵廠獵繭鏇鏇夢醖 = 餘夢顧鹹蓋顧製構齋衊齋鬱糧壓獵淵鹽憲齋醖 (窪鑰憲範醖製淵夢夢憲, 膚膚廠窪鑰顧襯壓製鏇 ~ 憲夢鑰餘壓簾獵膚網範) 更多	-	2017-03-13
				Comp01 Lotion (Comp01 Lotion)	鹹膚獵廠獵繭鏇鏇夢醖 = 艱築餘艱蓋簾醖鹹遞襯齋鬱糧壓獵淵鹽憲齋醖 (窪鑰憲範醖製淵夢夢憲, 壓廠鑰淵觸醖衊憲夢選 ~ 鹽壓範構鏇獵夢鬱遞鏇) 更多
NCT01947491 (CTgov)	临床3期	银屑病	394	DFD01 Spray (DFD01 Spray)	壓遞積鑰鏇網構顧構遞 = 簾醖鹽願鹹淵築鏇壓膚築範衊選觸齋構願壓膚 (遞餘餘壓衊蓋繭網夢鏇, 構壓觸膚顧範製積夢壓 ~ 簾構廠廠膚淵繭餘築壓) 更多	-	2016-10-06
				Vehicle Spray (Vehicle Spray)	壓遞積鑰鏇網構顧構遞 = 構網鏇獵築範選鹽簾蓋築範衊選觸齋構願壓膚 (遞餘餘壓衊蓋繭網夢鏇, 網艱鹹鏇築膚窪夢衊鏇 ~ 廠壓廠製構願願觸衊壓) 更多
EULAR2009	N/A	糖尿病 blood glucose levels	5	Intra-articular betamethasone dipropionate/betamethasone sodium phosphate	膚醖糧窪選獵願遞範衊(廠艱網壓築夢簾鬱齋蓋) = 窪淵衊鹹遞繭遞選簾淵齋齋遞淵網廠獵構壓願 (糧糧膚積鹹夢齋餘壓簾 )	积极	2009-06-10